Skip to main content
Clinical Trials/NCT02356705
NCT02356705
Completed
Phase 4

Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2

Jennifer Victory, RN, CCRC1 site in 1 country42 target enrollmentJanuary 2015

Overview

Phase
Phase 4
Intervention
saline placebo
Conditions
Sedation
Sponsor
Jennifer Victory, RN, CCRC
Enrollment
42
Locations
1
Primary Endpoint
Pediatric Pre-Induction Anesthesia Scale at Time of Mask Placement
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Midazolam is often given before surgery to sedate a patient before anesthesia is given. Children are often given a small dose either by mouth or squirted into the nose. Children will often spit out the oral midazolam, making it difficult to know how much medicine, if any, they have received. Giving midazolam into the nose is more reliable, but children may complain of pain, stinging, and may become upset due to the discomfort. Nosebleeds may also occur when midazolam is squirted alone into the nose. The purpose of this study is to see if adding a numbing medicine, xylocaine, to the nasal midazolam makes giving the midazolam easier and more comfortable without affecting how the midazolam works as a sedative. This is follow up to the pilot study, Project # 994. This will expand the previous study, with additional participants and revised xylocaine concentration

Registry
clinicaltrials.gov
Start Date
January 2015
End Date
December 2017
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Jennifer Victory, RN, CCRC
Responsible Party
Sponsor Investigator
Principal Investigator

Jennifer Victory, RN, CCRC

Clinical Research Nurse Supervisor

Bassett Healthcare

Eligibility Criteria

Inclusion Criteria

  • Children aged 18 months-7 years, scheduled for a minor Ear/Nose/Throat surgical procedure requiring mask anesthesia
  • American Society of Anesthesiologists (ASA) Class 1 or 2
  • Parent willing and able to provide written informed consent
  • Parent willing and able to complete the Observed Behavioral Distress (OBD) Visual Assessment Scale (VAS)

Exclusion Criteria

  • ASA Class 3 or greater
  • History of allergy to midazolam or xylocaine
  • Presence of acute respiratory infection at time of surgery
  • Parent unwilling or unable to provide informed consent
  • Parent unwilling or unable to complete the OBD VAS

Arms & Interventions

Saline Placebo

Control patients will receive intranasal saline

Intervention: saline placebo

Nasal Midazolam Only

Patients will receive 0.2 mg/kg of intranasal midazolam

Intervention: Midazolam

Midazolam Plus Xylocaine

Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.

Intervention: Midazolam

Midazolam Plus Xylocaine

Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.

Intervention: xylocaine

Outcomes

Primary Outcomes

Pediatric Pre-Induction Anesthesia Scale at Time of Mask Placement

Time Frame: 25 minutes

Pediatric Response to Mask Placement Scale - scaled scored by the anesthesiologist or certified nurse anesthetist (CRNA) at the time of mask placement * 1. Agitated: Previous criteria and/or refuses mask. (worst score) * 2. Alert: Previous criteria and/or initially refuses mask, but accept after persuasion. * 3. Calm: Previous criteria and accepts mask. * 4. Drowsy: Previous criteria and accepts mask. * 5. Asleep: Previous criteria and accepts mask. (best score)

Secondary Outcomes

  • Pediatric Pre-Induction Anesthesia Scale at Arrival to Operating Room(20 minutes)

Study Sites (1)

Loading locations...

Similar Trials